Generic Medicine Info
Cap: May be taken with or without food. Swallow whole w/ a full glass of water & in an upright position.
Granules: Should be taken with food.
Hypersensitivity. Topical and vaginal: History of inflammatory bowel disease, regional enteritis, ulcerative colitis or antibiotic-associated colitis. Neonates (parenteral).
Special Precautions
Patients with history of gastrointestinal disease (e.g. colitis); atopic individuals. Not intended for the treatment of meningitis. Not recommended for severe nodulocystic acne (topical lotion). Severe hepatic impairment. Debilitated patients. Children. Pregnancy and lactation. Patient Counselling Vaginal preparations may decrease the effectiveness of latex or rubber contraceptive agents (e.g. condoms, diaphragms). Monitoring Parameters Monitor CBC, LFT, and renal function periodically during prolonged treatment.
Adverse Reactions
Significant: Superinfection. Blood and lymphatic system disorders: Leucopenia, agranulocytosis, eosinophilia, neutropenia, thrombocytopenia. Gastrointestinal disorders: Diarrhoea, abdominal pain, nausea, vomiting, oesophagitis, oesephageal ulcer. General disorders and administration site conditions: Application site reactions (e.g. inflammation, irritation, burning sensation, pain, dryness, oiliness), inj site reactions (e.g. pain, irritation, abscess, induration). Hepatobiliary disorders: Jaundice. Immune system disorders: Urticaria. Infections and infestations: Cervicitis, vaginal candidiasis, vaginitis. Investigations: Abnormal LFT. Nervous system disorders: Dysgeusia, headache, dizziness. Renal and urinary disorders: Azotaemia, oliguria, proteinuria. Reproductive system and breast disorders: Vulvovaginal irritation, vaginal moniliasis. Skin and subcutaneous tissue disorders: Maculopapular rash, pruritus, erythema, seborrhoea, contact dermatitis. Vascular disorders: Hypotension (IV), thrombophlebitis (IV).
Potentially Fatal: Pseudomembranous colitis, Clostridium difficile-associated diarrhoea (CDAD), severe hypersensitivity reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS); gasping syndrome (in neonates).
Drug Interactions
May enhance the action of neuromuscular blocking agents. May antagonise the effects of parasympathomimetics. May competitively inhibit the effects of macrolides, ketolides, streptogramins, linezolid and chloramphenicol. May increase coagulation tests (e.g. prothrombin time, INR) and risk of bleeding with vitamin K antagonists (e.g. warfarin, acenocoumarol, fluindione). May decrease therapeutic effect with rifampicin. May reduce clearance with CYP3A4 and CYP3A5 inhibitors. Erythromycin may diminish therapeutic effect of clindamycin (topical).
ATC Classification
J01FF01 - clindamycin ; Belongs to the class of lincosamides. Used in the systemic treatment of infections.
G01AA10 - clindamycin ; Belongs to the class of antibiotics. Used in the treatment of gynecological infections.
D10AF01 - clindamycin ; Belongs to the class of topical antiinfective preparations used in the treatment of acne.
Disclaimer: This information is independently developed by CIMS based on clindamycin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in